• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Subtype Classification of Intrahepatic Cholangiocarcinoma Using Liver MR Imaging Features and Its Prognostic Value.利用肝脏磁共振成像特征对肝内胆管癌进行亚型分类及其预后价值
Liver Cancer. 2022 Mar 30;11(3):233-246. doi: 10.1159/000521747. eCollection 2022 Jun.
2
"Very early" intrahepatic cholangiocarcinoma (≤ 2.0 cm): MRI manifestation and prognostic potential.“非常早期”肝内胆管癌(≤2.0cm):MRI 表现与预后潜能。
Clin Radiol. 2024 Aug;79(8):608-617. doi: 10.1016/j.crad.2024.05.005. Epub 2024 May 7.
3
Preoperative subcategorization based on magnetic resonance imaging in intrahepatic cholangiocarcinoma.术前基于磁共振成像的肝内胆管细胞癌的亚分类。
Cancer Imaging. 2023 Feb 13;23(1):15. doi: 10.1186/s40644-023-00533-2.
4
LI-RADS Category on MRI Is Associated With Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study.MRI上的LI-RADS分类与肝内胆管癌术后复发相关:一项多中心研究
J Magn Reson Imaging. 2023 Mar;57(3):930-938. doi: 10.1002/jmri.28354. Epub 2022 Jul 14.
5
Impact of small duct- and large duct type on survival in patients with intrahepatic cholangiocarcinoma: Results from a German tertiary center.小胆管型和大胆管型对肝内胆管癌患者生存的影响:来自德国一家三级中心的结果。
Pathol Res Pract. 2022 Oct;238:154126. doi: 10.1016/j.prp.2022.154126. Epub 2022 Sep 16.
6
A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.肝内肿块型胆管细胞癌的影像学分类提案:导管型和实质型——临床病理意义。
Eur Radiol. 2019 Jun;29(6):3111-3121. doi: 10.1007/s00330-018-5898-9. Epub 2018 Dec 17.
7
Risk stratification for overall survival and recurrence-free survival after R0 resection for solitary intrahepatic mass-forming cholangiocarcinoma based on preoperative MRI and clinical features.基于术前 MRI 和临床特征的 R0 切除后单发肝内肿块型胆管细胞癌的总生存和无复发生存风险分层。
Eur J Radiol. 2023 Dec;169:111190. doi: 10.1016/j.ejrad.2023.111190. Epub 2023 Nov 7.
8
Heterogeneity of small duct- and large duct-type intrahepatic cholangiocarcinoma.小胆管型和大胆管型肝内胆管细胞癌的异质性。
Histopathology. 2024 May;84(6):1061-1067. doi: 10.1111/his.15162. Epub 2024 Feb 26.
9
MRI for Hepatitis B-Associated Intrahepatic Cholangiocarcinoma: A Multicenter Comparative Study.MRI 对乙型肝炎相关性肝内胆管细胞癌的诊断价值:一项多中心对比研究。
J Magn Reson Imaging. 2024 Mar;59(3):1093-1104. doi: 10.1002/jmri.28855. Epub 2023 Jun 13.
10
Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis.混合型肝细胞癌-胆管细胞癌:与肿瘤标志物和预后相关的 MRI 特征。
Eur Radiol. 2022 Jan;32(1):78-88. doi: 10.1007/s00330-021-08188-y. Epub 2021 Jul 19.

引用本文的文献

1
Contrast-enhanced ultrasound for diagnosing subtypes of intrahepatic cholangiocarcinoma: a comparative study with poorly differentiated hepatocellular carcinoma.超声造影诊断肝内胆管癌亚型:与低分化肝细胞癌的对比研究
Cancer Imaging. 2025 Aug 27;25(1):107. doi: 10.1186/s40644-025-00923-8.
2
Imaging findings of intrahepatic cholangiocarcinoma for prognosis prediction and treatment decision-making: a narrative review.用于预后预测和治疗决策的肝内胆管癌影像学表现:一项叙述性综述
Ewha Med J. 2024 Oct;47(4):e66. doi: 10.12771/emj.2024.e66. Epub 2024 Oct 31.
3
Preoperative scoring system for predicting microvascular invasion in intrahepatic cholangiocarcinoma using gadoxetate-enhanced MRI.使用钆塞酸二钠增强MRI预测肝内胆管癌微血管侵犯的术前评分系统
Eur Radiol. 2025 Jun 6. doi: 10.1007/s00330-025-11722-x.
4
Molecular and Histological Profiles and Relevant Imaging Signatures of Intrahepatic Cholangiocarcinoma.肝内胆管癌的分子和组织学特征及相关影像学特征
J Clin Transl Hepatol. 2025 Jun 28;13(6):504-515. doi: 10.14218/JCTH.2024.00410. Epub 2025 Apr 30.
5
Comparison of MRI and prognostic features of intrahepatic cholangiocarcinoma between patients with and without hepatitis B virus infection.乙型肝炎病毒感染患者与未感染患者肝内胆管癌的MRI及预后特征比较。
Abdom Radiol (NY). 2025 Jun 3. doi: 10.1007/s00261-025-05034-3.
6
A Preoperative Diagnostic Nomogram to Predict Tumor Subclassifications of Intrahepatic Cholangiocarcinoma.一种用于预测肝内胆管癌肿瘤亚分类的术前诊断列线图。
Cancers (Basel). 2025 May 17;17(10):1690. doi: 10.3390/cancers17101690.
7
An MRI-based fusion model for preoperative prediction of perineural invasion status in patients with intrahepatic cholangiocarcinoma.一种基于磁共振成像的融合模型,用于术前预测肝内胆管癌患者的神经周围侵犯状态。
World J Surg Oncol. 2025 Apr 26;23(1):164. doi: 10.1186/s12957-025-03819-w.
8
MRI-based microvascular invasion prediction in mass-forming intrahepatic cholangiocarcinoma: survival and therapeutic benefit.基于MRI的肿块型肝内胆管癌微血管侵犯预测:生存及治疗获益情况
Eur Radiol. 2024 Dec 19. doi: 10.1007/s00330-024-11296-0.
9
LI-RADS Category Can Be a Post-Surgical Prognostic Factor for Intrahepatic Cholangiocarcinoma in Patients with Liver Cirrhosis or Chronic Hepatitis B.肝脏影像报告和数据系统(LI-RADS)分类可作为肝硬化或慢性乙型肝炎患者肝内胆管癌的术后预后因素。
Liver Cancer. 2024 Jun 14;13(6):629-642. doi: 10.1159/000539794. eCollection 2024 Dec.
10
Classification of intrahepatic cholangiocarcinoma.肝内胆管癌的分类
Abdom Radiol (NY). 2025 Jun;50(6):2522-2532. doi: 10.1007/s00261-024-04732-8. Epub 2024 Dec 4.

本文引用的文献

1
Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.胆道癌的分子特征可预测化疗和程序性死亡 1/程序性死亡配体 1 阻断反应。
Hepatology. 2021 Oct;74(4):1914-1931. doi: 10.1002/hep.31862. Epub 2021 Jul 29.
2
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.胆管癌 2020:机制和管理的新前沿。
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30.
3
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.ivosidenib 治疗 IDH1 突变、化疗耐药性胆管癌(ClarIDHy):一项多中心、随机、双盲、安慰剂对照、3 期研究。
Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13.
4
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.肝内和肝外胆管癌的危险因素:系统评价和荟萃分析。
J Hepatol. 2020 Jan;72(1):95-103. doi: 10.1016/j.jhep.2019.09.007. Epub 2019 Sep 16.
5
The 2019 WHO classification of tumours of the digestive system.2019年世界卫生组织消化系统肿瘤分类。
Histopathology. 2020 Jan;76(2):182-188. doi: 10.1111/his.13975. Epub 2019 Nov 13.
6
Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging.肝细胞癌及其类似物的不典型表现:如何使用钆塞酸增强肝脏磁共振成像解决具有挑战性的病例。
Korean J Radiol. 2019 Jul;20(7):1019-1041. doi: 10.3348/kjr.2018.0636.
7
Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.联合肝细胞癌和肝内胆管癌的基因组和转录组分析揭示了不同的分子亚型。
Cancer Cell. 2019 Jun 10;35(6):932-947.e8. doi: 10.1016/j.ccell.2019.04.007. Epub 2019 May 23.
8
Differentiation of two subtypes of intrahepatic cholangiocarcinoma: imaging approach.两种肝内胆管细胞癌亚型的鉴别:影像学方法。
Eur Radiol. 2019 Jun;29(6):3108-3110. doi: 10.1007/s00330-019-06135-6. Epub 2019 Mar 26.
9
Intrahepatic Mass-forming Cholangiocarcinoma: Arterial Enhancement Patterns at MRI and Prognosis.肝内肿块型胆管细胞癌:MRI 动脉期增强模式与预后。
Radiology. 2019 Mar;290(3):691-699. doi: 10.1148/radiol.2018181485. Epub 2019 Jan 8.
10
A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.肝内肿块型胆管细胞癌的影像学分类提案:导管型和实质型——临床病理意义。
Eur Radiol. 2019 Jun;29(6):3111-3121. doi: 10.1007/s00330-018-5898-9. Epub 2018 Dec 17.

利用肝脏磁共振成像特征对肝内胆管癌进行亚型分类及其预后价值

Subtype Classification of Intrahepatic Cholangiocarcinoma Using Liver MR Imaging Features and Its Prognostic Value.

作者信息

Park Sungeun, Lee Youngeun, Kim Haeryoung, Yu Mi Hye, Lee Eun Sun, Yoon Jeong Hee, Joo Ijin, Lee Jeong Min

机构信息

Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.

Department of Radiology, Konkuk University Medical Center, Seoul, Republic of Korea.

出版信息

Liver Cancer. 2022 Mar 30;11(3):233-246. doi: 10.1159/000521747. eCollection 2022 Jun.

DOI:10.1159/000521747
PMID:35949291
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9218635/
Abstract

INTRODUCTION

Small-duct (SD) and large-duct (LD) subtypes of cholangiocarcinoma have been investigated for their prognostic factors. This study aimed to evaluate the diagnostic value of liver magnetic resonance imaging (MRI) in differentiating SD and LD types of intrahepatic cholangiocarcinoma (iCCA) and its prognostic value in predicting survival outcomes.

METHODS

One hundred forty patients with surgically confirmed iCCAs (93 SD type and 47 LD type) who had available preoperative gadoxetic acid-enhanced liver MR images were retrospectively included. MRI features suggestive of the LD type over the SD type were analyzed using multivariate logistic analyses. Postoperative recurrence-free survival (RFS) and overall survival (OS) for 107 patients with available survival data were compared according to MRI features.

RESULTS

MRI features suggestive of the LD type included infiltrative contour (odds ratio [OR] 14.2, 95% confidence interval [CI]: 2.5-81.7, = 0.003), diffuse biliary dilatation (OR 9.7, 95% CI: 1.2-76.9, = 0.032), no arterial phase hyperenhancement (OR 17.8, 95% CI: 2.7-118.6, = 0.003), and vascular invasion (OR 4.5, 95% CI: 1.3-15.4, = 0.018). When two or more features were combined, sensitivity was 59.6% (28/47), and specificity was 95.7% (89/93) in discriminating the LD type. RFS/OS was significantly shorter in patients with two or more MRI features, compared to those with none or one (310 days vs. 529 days, = 0.011/964 days vs. 2,023 days, = 0.010).

CONCLUSIONS

Preoperative liver MRI may help predict the pathological subtype of iCCAs as either the SD type or LD type, allowing preoperative identification of patients with poorer survival outcomes.

摘要

引言

胆管癌的小导管(SD)和大导管(LD)亚型的预后因素已得到研究。本研究旨在评估肝脏磁共振成像(MRI)在鉴别肝内胆管癌(iCCA)的SD和LD类型中的诊断价值及其在预测生存结局方面的预后价值。

方法

回顾性纳入140例经手术确诊的iCCA患者(93例SD型和47例LD型),这些患者术前均有钆塞酸增强肝脏MR图像。使用多因素逻辑分析来分析提示LD型而非SD型的MRI特征。根据MRI特征比较了107例有生存数据的患者的术后无复发生存期(RFS)和总生存期(OS)。

结果

提示LD型的MRI特征包括浸润性轮廓(优势比[OR] 14.2,95%置信区间[CI]:2.5 - 81.7,P = 0.003)、弥漫性胆管扩张(OR 9.7,95% CI:1.2 - 76.9,P = 0.032)、动脉期无强化(OR 17.8,95% CI:2.7 - 118.6,P = 0.003)和血管侵犯(OR 4.5,95% CI:1.3 - 15.4,P = 0.018)。当两种或更多特征组合时,鉴别LD型的敏感性为59.6%(28/47),特异性为95.7%(89/93)。与无或有一个MRI特征的患者相比,有两种或更多MRI特征的患者的RFS/OS显著更短(310天对529天,P = 0.011/964天对2023天,P = 0.010)。

结论

术前肝脏MRI可能有助于预测iCCA的病理亚型是SD型还是LD型,从而在术前识别出生存结局较差的患者。